Compare PPG Industries, Inc. (PPG) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PPG Industries, Inc. vs TG Therapeutics Inc — how do they compare? PPG Industries, Inc. trades at $117.3 (market cap $25.79B), while TG Therapeutics Inc trades at $52.7 (market cap $8.26B). The key difference: PPG Industries, Inc. is far larger — about 3.1× TG Therapeutics Inc's market cap, and PPG Industries, Inc. pays a 2.56% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| PPG | TGTX | |
|---|---|---|
Market Cap | $25.79B | $8.26B |
Sector | Basic Materials | Health |
52-Week High | $131.56 | $59.06 |
52-Week Low | $94.34 | $26.39 |
Enterprise Value | $31.90B | $8.50B |
Dividend Yield | 2.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PPG Industries trades at $115.71, down 1.41% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 results with $15.88B revenue and $1.58B net income, and recently raised its dividend to $0.74 per share, reflecting confidence in cash flow. Analyst consensus is bullish with a $132.20 price target, though Q2 2026 earnings due July 28 are key for near-term direction.
The outlook is positive given solid profitability and dividend growth, but risks include economic sensitivity and debt levels. Upside potential exists if Q2 earnings beat expectations, while a miss could pressure the stock. The current valuation at a P/E of 16.58 appears reasonable relative to historical performance.
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About PPG Industries, Inc.
PPG is a global producer of coatings. The company is the world's largest producer of coatings after the purchase of selected Akzo Nobel assets. PPG's products are sold to a wide variety of end users, including the automotive, aerospace, construction, and industrial markets. The company has a footprint in many regions around the globe, with less than half of sales coming from North America in recent years. PPG is focused on its coatings and specialty products and expansion into emerging regions, as exemplified by the Comex acquisition.
Read more on PPG →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
